Researchers have identified an immune cell type with an apparently critical role in multiple sclerosis, and a way to block its entry into the brain.
A group of researchers identified adverse and previously unknown drug reactions by sifting through millions of social health forum posts.
Researchers have found a way to turn off a key driver of inflammation in celiac disease, an autoimmune disease that affects millions of Americans.
A promising anti-cancer therapy works great at first, but then loses its punch. A clever workaround may provide high-octane efficacy, without side effects.
Tuberculosis is a major public health problem worldwide, yet most people lack access to quick, reliable testing. Now, chemists have found a solution.
Stanford researcher Hiromitsu Nakauchi explores his dream of growing custom-made, transplantable human organs in large animals, despite funding difficulties.
Should research findings be moved to the clinic as soon as possible or should things move more slowly for patient safety? A med student explores the issues.
New research suggests that targeting mitochondria could be a way to treat Parkinson's disease.
This Stanford Medicine study clarifies the underlying biology of high-grade serous ovarian cancer and could help lead to future therapies.
Stanford pain expert Beth Darnall discusses her clinical trials on methods to taper opioid doses for patients with chronic pain.
Mentally running through a routine improves performance. A new tool – brain-machine interface – sheds light on how.
A comparison of diets for weight loss for those with different levels of insulin and metabolic genes did not find a clear winner.
Even adults who are not considered "high-risk" should be tested to reduce deaths and improve cure rates, new Stanford Health Policy research suggests.
A new study suggests that a blood test following exercise may be a good way to differentiate between people who have ME/CFS and people who don't.
A look at the lab and work of Brian Kobilka, who won the 2012 Nobel Prize in Chemistry.
Stanford researchers led work on a possible cancer vaccine that involves injecting two immune-stimulating agents directly into solid tumors.
